Allorion Raises $40 Million in A Round for Novel Oncology and Autoimmune Therapies

Allorion Therapeutics of Boston and Guangzhou completed a $40M Series A financing to develop next-gen precision medicines for oncology and autoimmune disease. Allorion claims its discovery platform combines technological breakthroughs in protein  structure, big data, machine learning and gene editing. The platform delivers highly selective small molecules, including covalent and allosteric inhibitors of well-validated  targets. Allorion is completing IND-enabling studies and IND applications for two drug candidates in China and the US . The A round was led by Qiming Venture Partners. More details.... Share this with colleagues: // //